Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3092-3098

  Young, Scott D ^a   Whissell, Mark ^a   Noble, Jonathan C S ^a   Cano, Pablo O ^a   Lopez, Pedro G ^a   Germond, Colin J ^a  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MINOCYCLINE; ROFECOXIB; VINBLASTINE;

ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; FEMALE; HUMAN; JOB PERFORMANCE; LIFE EXPECTANCY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; NEOPLASMS; SULFONES; VINBLASTINE;

EID: 33744799963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2255     Document Type: Article

References (50)

1. Browder T, Butterfield C, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
2. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;8:1045-7.
3. Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
4. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
5. Zhang L, Yu D, Hicklin DJ, et al. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 2002;62:2034-42.
6. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-2.
7. Hermans IF, Chong TW, Palmowski MJ, et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63: 8408-13.
8. Subongkot S, Frame D, Leslie W, et al. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003;23: 9-28.
9. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tum Res Basel, Karger 2003;37:179-92.
10. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004;28:127-42.
11. Duivenvoorden W, Hirte H, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997;17:312-22.
12. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 1996;93: 2002-7.
13. Golub LM, McNamara TF, D'Angelo G, et al. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987;66: 1310-4.
14. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988;6:1501-15.
15. Kurzen H, Schmitt S, Naher H, et al. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 2003;14:515-22.
16. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
17. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.
18. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangeiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003;100:12917-22.
19. Kaur H, Budd GT. Metronomic therapy for breast cancer. Breast Cancer 2004;6:49-52.
20. Kamen BA, Rubin E, Aisner J, et al. High-time chemotherapy or high time for low dose. J Clin Oncol 2000;18:2935-7.
21. Mross K. Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist Updat 2000;3:223-35.
22. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7: 427-36.
23. Kerbel RS, Klement G, Pritchard K, et al. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (editorial) 2002;13:12-5.
24. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet 2001;2:733-40.
25. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220:545-54.
26. Stoll BR, Migliorini C, Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003;102:2555-60.
27. Kerbel R, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4: 423-36.
28. Little R, Wittes ER, Longo DL, et al. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998;16: 584-8.
29. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55.
30. Nihei Y, Suzuki M, Okano A, et al. Evaluation of anti-vascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90:1387-96.
31. Sersa G, Krzic M, Sentjuc M, et al. Reduced tumor oxygenation by treatment with vinblastine. Cancer Res 2001;61:4266-71.
32. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
33. Glode LH, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone in prostate carcinoma. Cancer 2003;98:1643-8.
34. Rehman S, Jayson GC. Molecular imaging of anti-angiogenic agents. Oncologist 2005;10:92-103.
35. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Eng J Med 1992;326:1745-51.
36. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-6.
37. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004;93:275-8.
38. Chow LWC, Toi M, Takebayashi Y, et al. Phase II study of the preoperative use of celecoxib (CELEBREX™) and FEC for the treatment of locally advanced breast cancer. Breast Cancer Res Treat 2003:82.
39. Altorki NK, Keresztes JL, Port DM, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-50.
40. Blanke CD, Benson AB, Dragovich T, et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). ASCO Proc 2002;21:127a.
41. Enzinger PC, Mamon H, Bueno R, et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. ASCO Proc 2003;361.
42. Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-8.
43. Pannullo S, Serventi JV, Balmaceda C, et al. Temozolomide plus celecoxib for treatment of malignant gliomas. ASCO Proc 2003;22:114.
44. Buckstein R, Crump M, Foden C, et al. High dose celecoxib and low dose cyclophosphamide for relapsed aggressive histology NHL. ASCO Proc 2003;22:206.
45. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004;171:1027-8.
46. Zhu J, Song X, Lin H, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-57.
47. Masumori N, Tsukamoto T, Miyao N, et al. Inhibitory effect of minocycline on in vitro invasion and experimental metastasis of mouse renal adenocarcinoma. J Urol 1994;151:1400-4.
48. Masumori N, Miyao N, Takahashi A, et al. Minocycline inhibits in vitro invasion and experimental pulmonary metastasis of mouse renal adenocarcinoma. Adv Dent Res 1998;12:111-13.
49. Duivenvoorden WCB, Popovic SV, Lhotak S, et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res 2002;62:1588-91.
50. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995;36:227-36.